Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 61 citing articles:

Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes
Xueyuan Guo, Caihua Sang, Ribo Tang, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. S1, pp. 53-63
Open Access | Times Cited: 7
Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database
Lin Zhang, Wei Mao, Xingxing Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Abhishek Gami, Roger S. Blumenthal, Darren K. McGuire, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 2
Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study
Derin Karacabeyli, Diane Lacaille, Na Lü, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0308533-e0308533
Open Access | Times Cited: 2
Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33
Abhipree Sharma, Miles J. De Blasio, Rebecca H. Ritchie
British Journal of Pharmacology (2022) Vol. 180, Iss. 22, pp. 2916-2933
Open Access | Times Cited: 11
Health Effects of Metabolic Risks in the United States From 1990 to 2019
Ruifang Chen, Saeid Safiri, Masoud Behzadifar, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 9
Shared decision making, diagnostic evaluation, and pharmacotherapy in type 2 diabetes
Christina Brockamp, Rüdiger Landgraf, Ulrich Müller, et al.
Deutsches Ärzteblatt international (2023)
Open Access | Times Cited: 5
Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
Mei Qiu, Limin Zhao, Ze‐Lin Zhan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 11
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Closed Access | Times Cited: 4
Atherosclerotic Cardiovascular Disease Risk and Longitudinal Risk Factor Management Among Patients With Breast Cancer
John W. Melson, Benjamin Koethe, Sharanya Mohanty, et al.
Clinical Breast Cancer (2023) Vol. 24, Iss. 2, pp. e71-e79.e4
Open Access | Times Cited: 4
Impact of Pre-existing Type 2 Diabetes Mellitus and Cardiovascular Disease on Healthcare Resource Utilization and Costs in Patients With COVID-19
Chi Nguyen, Christopher L. Crowe, Effie Kuti, et al.
Journal of health economics and outcomes research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Improving English Pronunciation Through Phonetics Instruction in Yemeni EFL Classrooms
Fadhl Mohammed Awadh Mohammed Awadh, Nur Hidayanto Pancoro Setyo Putro, Albert Efendi Pohan, et al.
Journal of Languages and Language Teaching (2024) Vol. 12, Iss. 2, pp. 930-930
Open Access | Times Cited: 1
Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
LiGang Huang, Rong Hu, HaiTao Zou
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Sex-specific Cardiovascular Risk Factors and Treatment in Females with T2DM and CVD: Developments and Knowledge Gaps
Erin S. LeBlanc, Neon Brooks, Melinda Davies, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 12, pp. e2167-e2177
Open Access | Times Cited: 1
Female is Associated with Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes
Yiting Wang, Yikun Zhou, Yonghong Zhang, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 2355-2364
Open Access | Times Cited: 3
Clinical Effects of Sacubitril/Valsartan Combined with Dapagliflozin in Patients with Diabetes and ST-segment Elevation Myocardial Infarction
Zhengbin Wang, Zhifang Li, Yiming Hou, et al.
Cardiovascular Innovations and Applications (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 2
Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors
Dimitrios Karagkounis
Drug and Therapeutics Bulletin (2023) Vol. 61, Iss. 7, pp. 103-107
Closed Access | Times Cited: 2
Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus
Stewart G. Albert, Ekta Shrestha, Vaishaliben Ahir
Endocrine Practice (2023) Vol. 30, Iss. 3, pp. 246-252
Closed Access | Times Cited: 2
Effect of genetic polymorphisms on the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in treatment of type 2 diabetes mellitus
Ю. Г. Самойлова, М.В. Матвеева, Anastasia E. Stankova, et al.
Russian Journal of Preventive Medicine (2024) Vol. 27, Iss. 1, pp. 67-67
Closed Access
Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
Ю. Г. Самойлова, О. Е. Ваизова, Anastasia E. Stankova, et al.
Terapevticheskii arkhiv (2024) Vol. 96, Iss. 1, pp. 63-67
Open Access
INVESTIGANDO OS EFEITOS CARDIOVASCULARES DE NOVOS AGENTES REDUTORES DE GLICOSE EM PACIENTES COM DIABETES E DOENÇA ARTERIAL CORONARIANA
Giovana Sena Veloso Stefani Moreira, Larissa Teixeira Reis, Lucas Coutinho Orellana, et al.
Revista Ibero-Americana de Humanidades, Ciências e Educação (2024) Vol. 10, Iss. 6, pp. 1823-1832
Open Access
Meta-analysis of the efficacy and impact on cardiac function of sodium–glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients
Weidong Li, Xuanyang Shen, Meiqi Zhang, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40409-e40409
Open Access
Magnitude, Distribution and Contextual Risk Enhancing Predictors of High 10-Year Cardiovascular Risk Among Diabetic Patients in Tanzania
Nadeem Kassam, Salim Surani, Kamran Hameed, et al.
Patient Related Outcome Measures (2023) Vol. Volume 14, pp. 87-96
Open Access | Times Cited: 1
Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
Ю. Г. Самойлова, Anastasia E. Stankova, М.В. Матвеева, et al.
Russian Journal of Preventive Medicine (2023) Vol. 26, Iss. 12, pp. 95-95
Closed Access | Times Cited: 1
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss
Edward J. Modestino, Abdalla Bowirrat, Kai‐Uwe Lewandrowski, et al.
Acta Scientific Neurology (2024), pp. 12-18
Open Access

Scroll to top